Related Experiment Videos
[Hypersplenism in liver cirrhosis]
1Second Department of Internal Medicine, Faculty of Medicine, Kyushu University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 1, 1994
Summary
Hypersplenism, a condition linked to enlarged spleen and low blood counts, can be treated with partial splenic embolization. This procedure improves blood cell counts and liver function markers in patients with cirrhosis.
Area of Science:
- Gastroenterology and Hepatology
- Hematology
- Interventional Radiology
Context:
- Hypersplenism is characterized by splenomegaly and cytopenias, frequently observed in liver cirrhosis and portal hypertension.
- Traditional treatments like portacaval shunt have variable outcomes, and splenectomy carries risks such as sepsis.
- Partial splenic embolization (PSE) has emerged as a minimally invasive therapeutic option.
Purpose:
- To evaluate the efficacy and safety of partial splenic embolization in patients with hypersplenism, particularly those with liver cirrhosis.
Summary:
- Partial splenic embolization involves injecting gelform into the splenic artery to reduce spleen size and function.
- The procedure leads to a significant increase in circulating blood cell counts (anemia, leukopenia, thrombocytopenia).
- Key liver function markers, including albumin, hepaplastintest, cholesterol, and cholinesterase, show significant improvement post-embolization.
Impact:
- Partial splenic embolization offers a beneficial alternative to splenectomy for managing hypersplenism, with a low complication rate.
- This interventional technique can improve hematological parameters and biochemical liver function tests in patients with cirrhosis.
- PSE represents a promising approach to mitigate the complications associated with hypersplenism in liver disease.